Registration Now Open For Tribe Public’s Webinar Event “Advancing a Unique Broad-based Vaccine Approach to Fighting COVID...
March 01 2021 - 09:00AM
via NewMediaWire --
GeoVax Labs, Inc. (NasdaqCM: GOVX)
(“GeoVax” or the “Company”), a biotechnology company developing
human immunotherapies and vaccines against infectious diseases and
cancer, announces that Chairman & CEO, David Dodd and CFO, Mark
Reynolds will present at Tribe Public’s Webinar Presentation and
Q&A Event titled “Advancing a Unique Broad-based Vaccine
Approach to Fighting COVID-19, Ebola & Beyond”. The Event is
scheduled to begin at 8:30 am Pacific/11:30 am Eastern on
Wednesday, March 3, 2021.
To register to join the complimentary, ZOOM webinar-based event,
please visit Tribe Public LLC at GeoVax2021.TribePublic.com. Once
registered, participants may begin forwarding their questions for
GeoVax’s management to Tribe Public at
http://research@tribepublic.com or share their questions via the
ZOOM chat feature during the event. Tribe Public’s Managing Member,
John F. Heerdink, Jr., will host the event and relay all questions
to management.
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company
developing human vaccines against infectious diseases and cancer
using a novel patented Modified Vaccinia Ankara-Virus Like Particle
(MVA-VLP) based vaccine platform. On this platform, MVA, a large
virus capable of carrying several vaccine antigens, expresses
proteins that assemble into VLP immunogens in the person receiving
the vaccine. The production of VLPs in the person being vaccinated
can mimic virus production in a natural infection, stimulating both
the humoral and cellular arms of the immune system to recognize,
prevent, and control the target infection. The MVA-VLP derived
vaccines can elicit durable immune responses in the host similar to
a live-attenuated virus, while providing the safety characteristics
of a replication-defective vector.
GeoVax’s current development programs are focused on preventive
vaccines against COVID-19, HIV, Zika Virus, hemorrhagic fever
viruses (Ebola, Sudan, Marburg, and Lassa), and malaria, as well as
therapeutic vaccines against multiple cancers. The Company has
designed a preventive HIV vaccine candidate to fight against the
subtype of HIV prevalent in the commercial markets of the Americas,
Western Europe, Japan, and Australia; human clinical trials for
this program are managed by the HIV Vaccine Trials Network (HVTN)
with the support of the National Institutes of Health (NIH).
GeoVax’s HIV vaccine is also part of two separate collaborative
efforts to apply its innovative gene therapy approach toward a
functional cure for HIV.
About Tribe Public LLC
Tribe Public LLC is a San Francisco, CA-based organization that
hosts complimentary worldwide webinar & meeting events in the
U.S. Tribe’s events focus on issues that the Tribe’s members care
about with an emphasis on hosting management teams and experts from
publicly traded companies from all sectors & financial
organizations that are seeking to increase awareness of their
products, progress, and plans. Tribe members primarily include
Institutions, Family Offices, Portfolio Managers, Registered
Investment Advisors, Accredited Investors, Sell Side Analysts, and
members of media. Tribe Members are encouraged to express their
interest in speakers at the Tribe Public website via the Tribe’s
FREE “Wish List” process. Visit Tribe Public’s Website
http://www.tribepublic.com/ to join the Tribe and express your
interests today.
Company Contact:GeoVax Labs,
Inc.investor@geovax.com678-384-7220
GeoVax Labs (NASDAQ:GOVX)
Historical Stock Chart
From Feb 2024 to Mar 2024
GeoVax Labs (NASDAQ:GOVX)
Historical Stock Chart
From Mar 2023 to Mar 2024